Physician profile
Veena Chandrakar
NPI 1295738342
$94,227.14
in general payments reported to CMS, 2019-2025
72 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,737 · 2020: $9,693 · 2021: $22K · 2022: $21K · 2023: $22K · 2024: $12K · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Food and Beverage: $7,927 · Consulting Fee: $5,194 · Travel and Lodging: $1,351 · Education: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,975.00 |
| Food and Beverage | $7,927.44 |
| Consulting Fee | $5,194.00 |
| Travel and Lodging | $1,351.35 |
| Education | $537.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $38,418.65 | 2022-2025 | |
| Dova Pharmaceuticals | $15,419.10 | 2019-2021 | |
| Sirtex Medical INC | $14,659.10 | 2019-2025 | Sir-Spheres Microspheres |
| Regeneron Pharmaceuticals, INC. | $3,825.77 | 2023-2024 | Libtayo |
| Celgene Corporation | $3,165.18 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Genzyme Corporation | $2,856.37 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,803.16 | 2021-2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $1,164.53 | 2019-2025 | Opdivo, Opdualag |
| Amgen INC. | $1,145.66 | 2019-2024 | Kyprolis, Evenity, Prolia |
| Merck Sharp & Dohme LLC | $934.88 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals Lp | $743.33 | 2019-2025 | Enhertu, Tagrisso, Lynparza |
| Janssen Biotech, INC. | $728.22 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Cti Biopharma Corp. | $666.66 | 2022 | |
| Novartis Pharmaceuticals Corporation | $651.57 | 2019-2025 | |
| Astellas Pharma US INC | $590.16 | 2019-2025 | Padcev, Xtandi, Vyloy |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $536.77 | 2019-2025 | Verzenio, Jaypirca |
| Myriad Genetic Laboratories, INC. | $462.49 | 2021-2025 | Myrisk, Precisetumor |
| Pfizer INC. | $393.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $369.94 | 2020-2025 | Ojjaara, Blenrep |
| Tempus Ai, INC | $338.90 | 2024-2025 | Xt Cdx |
| Incyte Corporation | $326.87 | 2020-2025 | Monjuvi, Jakafi |
| Pharmaessentia USA Corporation | $274.79 | 2022-2024 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.90 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $265.82 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Alexion Pharmaceuticals, INC. | $240.55 | 2023-2025 | Ultomiris, Soliris |
| Eisai INC. | $236.09 | 2021-2025 | |
| Puma Biotechnology, INC. | $235.15 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $221.31 | 2019-2025 | Tavalisse, Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $216.98 | 2019-2025 | |
| Beigene USA, INC. | $208.08 | 2020-2024 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $180.27 | 2022-2025 | Fotivda |
| Amag Pharmaceuticals, INC. | $166.85 | 2019-2022 | |
| Daiichi Sankyo INC. | $162.00 | 2019-2024 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $145.14 | 2021-2022 | |
| Seagen INC. | $143.75 | 2020-2023 | Padcev, Adcetris |
| Sanofi-Aventis U.S. LLC | $141.47 | 2021-2025 | |
| Gilead Sciences, INC. | $132.64 | 2021-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $128.85 | 2019-2021 | |
| Genentech USA, INC. | $122.61 | 2021-2024 | Tecentriq, Lunsumio, Polivy |
| Springworks Therapeutics, INC. | $109.40 | 2024 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $107.94 | 2022-2024 | Empaveli |
| Emd Serono, INC. | $92.78 | 2019-2025 | Bavencio |
| Blueprint Medicines Corporation | $92.03 | 2024-2025 | Ayvakit |
| Kyowa Kirin, INC. | $83.49 | 2020-2024 | Poteligeo |
| Abbvie INC. | $81.49 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $70.29 | 2020-2024 | Onivyde |
| Mylan Institutional INC. | $63.73 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $60.83 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $58.50 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.53 | 2019-2021 | |
| Morphosys, US INC. | $55.36 | 2021-2023 | Monjuvi |
| Exelixis INC. | $54.53 | 2019-2024 | Cabometyx |
| Clovis Oncology, INC. | $49.35 | 2019-2021 | |
| Myovant Sciences INC. | $49.14 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $47.73 | 2021-2023 | Xpovio |
| Tactile Systems Technology INC | $40.17 | 2020-2024 | Entre Plus, Flexitouch Plus |
| Pharmacosmos Therapeutics INC. | $36.21 | 2023 | Monoferric |
| Alnylam Pharmaceuticals INC. | $33.17 | 2023-2024 | Givlaari |
| Sanofi US Services INC. | $31.84 | 2024 | |
| Immunocore Limited | $29.04 | 2023 | Kimmtrak |
| Spectrum Pharmaceuticals INC. | $28.95 | 2024 | Rolvedon |
| Fennec Pharmaceuticals, INC. | $24.16 | 2024 | Pedmark |
| Tersera Therapeutics LLC | $24.10 | 2024 | Zoladex |
| Deciphera Pharmaceuticals INC. | $20.51 | 2022 | |
| G1 Therapeutics, INC. | $19.94 | 2023 | Cosela |
| Servier Pharmaceuticals LLC | $19.11 | 2021 | |
| Sumitomo Pharma America, INC. | $18.93 | 2025 | Orgovyx |
| Secura Bio, INC. | $17.86 | 2021 | |
| Chiesi USA, INC. | $16.38 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.87 | 2020 | |
| Tesaro, INC. | $14.61 | 2019 | |
| Global Blood Therapeutics, INC. | $14.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veena Chandrakar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.